Global tensions, trade barriers, and shifting alliances are changing how life science companies operate, invest, and innovate. The sector – including pharmaceuticals, biotechnology, and medical technology – faces growing geopolitical risks. Trade disputes, national security priorities, and evolving supply chains now directly affect research funding and the availability of essential medicines. Life sciences, closely linked to science parks, have shifted from a global, cost-focused model to one where nations treat pharmaceutical production, data, and R&D as strategic security assets, positioning health as sovereign infrastructure.
At World Economic Forum Annual Meeting 2026 in Davos, geopolitics was identified as a primary force reshaping the global life sciences landscape, with geoeconomic confrontation named a top global risk. A clear message emerged across panels, dialogues, and roundtables: life sciences do not operate in isolation. The sector has become a competitive arena where nations seek advantage, technologies converge, and market dynamics rapidly shift. In this context, intersecting trends in trade and policy, innovation, operations, and competition shape the industry more than any single factor, underscoring why 2026 is pivotal for long-term strategy.
Geopolitics is shifting the global life sciences sector from hyper-globalisation to a more regional, fragmented system focused on resilience, national security, and partner-shoring. The industry is reducing its dependence on volatile supply chains, especially those linked to China, and diversifying manufacturing to regions such as India and Brazil. Europe, for example, faces increasing pressure to stay competitive as global dynamics evolve, particularly due to US–China competition in biotech and pharmaceuticals. Companies must now carefully choose locations for trials, manufacturing, sourcing, and R&D investment.
Beyond geographic shifts, science parks and the life sciences industry face significant geopolitical challenges. Trade disputes, tariffs, and rising economic nationalism have exposed weaknesses in global supply chains, leading to delays, higher costs, and strategic adjustments across the sector. In response to restrictive US immigration policies under the Trump administration, the European Union launched “Choose Europe for Science” to attract international scientific talent with substantial funding.
Governments and multinational companies now consider life sciences essential to national security and economic growth. Reports from Novartis and the German consulting firm Vality One highlight a growing consensus that strengthening domestic life science ecosystems is critical for resilience.
Science parks and the life sciences industry are increasingly interconnected through cross-sector collaboration and are both being reshaped by geopolitics. As sustainable development and technological sovereignty become global priorities, these ecosystems will likely grow even more connected. The next phase will be defined by innovation and how nations balance openness with resilience.
Three key takeaways emerged from the Davos forum. First, life sciences are undergoing a critical shift driven by geopolitics, fragmentation, and sovereign health strategies. Second, success will depend on rapidly scaling innovation, integrating AI across operations, and building resilience. Finally, competition and cooperation are intensifying as Big Tech transforms data, access, and value flows throughout the industry.
